Markov Cohort Model
The evaluation used a retrospective cost-effectiveness analysis from the Canadian health-sector perspective. The model was calibrated to Canadian fatal overdose data from 2020 through 2023. The model excluded opioid agonist therapy and pre…
1 sources - 5 claims
The evaluation used a retrospective cost-effectiveness analysis from the Canadian health-sector perspective. The model was calibrated to Canadian fatal overdose data from 2020 through 2023. The model excluded opioid agonist therapy and prescribed safer supply states because NORS was represented as a point-of-overdose intervention. Costs and health outcomes were modelled using a Markov cohort model with monthly cycles and age-specific time-varying mortality. The model population consisted of people actively using illicit drugs who could benefit from virtual overdose monitoring.